Penumbra Q4 revenue $385.4M (+22.1%); operating income $59.2M; FY25 rev $1.4B (+17.5%)

Penumbra Inc

2025-FY EPS reported $4.52 revenue$1,403,665,000

Revenue $385.4M for Q4, up 22.1% YoY (20.9% constant currency). US Thrombectomy $203.1M (+12.4%).
Gross margin 68.0% vs 66.8% a year ago; operating margin 15.4%.
Net income $47.3M; adjusted EBITDA $79.1M (20.5% margin).
Full year revenue $1,403.7M, up 17.5%; net income $177.7M; adjusted EBITDA $266.8M.
Embolization & access revenue grew 37.0% in Q4; international revenue up 27.7% (21.9% constant currency).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.